Remove 2028 Remove Patients Remove Prescription
article thumbnail

US companies drive 2023 drug launches positioned for blockbuster success by 2028

Pharmaceutical Technology

According to GlobalData’s Looking Ahead to 2023 – the Future of Pharma report, five drugs set for approval in 2023 are projected to attain blockbuster status or near-blockbuster status by 2028 with US company dominance. These drugs are set to make a combined $4.34bn in sales in 2028. Similarly, Almirall S.A.,

Sales 105
article thumbnail

Elite Teledentistry Companies in the USA

Medico Reach

Teledentistry has made dental services easily accessible to patients. million by 2028 , with more teledentistry companies entering the market. LiveDentist connects patients with certified dental experts to receive immediate treatment, consultation, and suggestions. Customers can avail dental services right from their comfort.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Pharma’s reputational high will be short-lived

World of DTC Marketing

Another biologic, Enbrel, on the market since 1998, will not have its $5 billion in sales challenged until the end of 2028. Billions in excess drug costs are shouldered by employers, taxpayers and patients as a result. I’m not sure why so many people make the jump from wanting to help patients to “what’s the ROI?

Pharma 186
article thumbnail

Ipsen beefs up in oncology, buying US biopharma Epizyme

pharmaphorum

The bolt-on deal comes shortly after Ipsen announced plans to sell its consumer health business for around €350 million, leaving it as a pure-play prescription pharma operating in the cancer, rare diseases and neuroscience categories. Ipsen is offering $1.45 Ipsen’s CVR offer includes $0.30

article thumbnail

Five points on CMS’s first ten picks for price negotiations

Clarivate

While more expensive than type 2 diabetes drugs, blood thinners follow a similar pattern of high prescription volumes. The dearth of cancer drugs (only blood cancer drug Imbruvica made this first list) stems from CMS only pursuing negotiations for Part D drugs in 2026 and 2027, then expanding to Part B drugs in 2028. With 27.5%

article thumbnail

Compliance to convenience: understanding the latest innovations in capsule formulation

Pharmaceutical Technology

When it comes to pharmaceutical, nutritional or cosmeceutical dosing, some of the most crucial parameters are safety, product effectiveness and patient adherence. Softgel capsules, containing a liquid, paste or emulsion active ingredient, are trusted and favoured by many patients. billion by 2028, at a CAGR of 12.6%.

article thumbnail

Consequences of the First 10 Drugs Selected for Medicare’s Negotiation Program

PM360

As many in the industry now know, the Inflation Reduction Act (IRA) is the most significant reform of Medicare prescription drug coverage since the creation of Part D and has wide-ranging implications for the healthcare industry. However, the impact of the new law will reverberate in the industry for years to come.